A5009501042- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- Viral gastroenteritis research and epidemiology
- vaccines and immunoinformatics approaches
- Animal Virus Infections Studies
- Influenza Virus Research Studies
- COVID-19 Impact on Reproduction
- Monoclonal and Polyclonal Antibodies Research
- Viral Infections and Outbreaks Research
- Bacillus and Francisella bacterial research
- COVID-19 epidemiological studies
- Disaster Response and Management
- Immunotherapy and Immune Responses
University of Cambridge
2021-2024
Vaccines in use against SARS-CoV-2 induce immune responses the spike protein. There is intense interest whether antibody response induced by vaccines will be robust new variants, as well next-generation for previously infected or immunized individuals.
The accelerated development of the first generation COVID-19 vaccines has saved millions lives, and potentially more from long-term sequelae SARS-CoV-2 infection. most successful vaccine candidates have used full-length spike protein as an immunogen. As expected RNA viruses, new variants evolved quickly replaced original wild-type SARS-CoV-2, leading to escape natural infection or induced immunity provided by sequence. Next that confer specific targeted broadly neutralising epitopes on...
As of June, 2021, the UK population is only partly vaccinated against COVID-19, with many people having received just one vaccination dose (either BNT162b2 [Pfizer–BioNTech]) or ChAdOx1 nCoV-19 [AZD1222; Oxford–AstraZeneca]). Tracking spread SARS-CoV-2 Variants Concern (VOCs) remains important for understanding levels vaccine-induced immunity and identifying emergence vaccine escape variants. The immune correlates protection to COVID-19 established in phase 3 clinical trials following two...
Despite the success of COVID-19 vaccination programmes in reducing morbidity and mortality, a substantial number individuals general population respond poorly to SARS-CoV-2 vaccination.1,2 Furthermore, only about 20% throughout low-income countries have received their first dose vaccine.3 Neutralising antibodies are key correlate protection from COVID-19, with booster vaccines offered increase new variants.4,5 However, poor responsiveness immunisation increases risk infection disease.
Immunodeficient patients (IDPs) are at higher risk of contracting severe coronavirus disease 2019 (COVID-19). Targeted vaccination strategies have been implemented to enhance vaccine-induced protection. In this population, however, clinical effectiveness is variable and the duration protection unknown.We sought better understand cellular humoral immune responses mRNA adenoviral vectored COVID-19 vaccines in with immunodeficiency.Immune acute respiratory syndrome 2 spike were assessed after...
One of the unexpected outcomes COVID-19 pandemic was relatively low levels morbidity and mortality in Africa compared to rest world. Nigeria, Africa's most populous nation, accounted for less than 0.01% global fatalities. The factors responsible Nigeria's loss life due are unknown. Also, correlates protective immunity SARS-CoV-2 impact pre-existing on outcome yet be elucidated. Here, we evaluated natural vaccine-induced immune responses from vaccinated, non-vaccinated convalescent...
Abstract Elucidating the adaptive immune characteristics of natural protection to Lassa fever (LF) is vital in designing and selecting optimal vaccine candidates. With rejuvenated interest LF a call for accelerated research on virus (LASV) vaccine, there need define correlates protective responses LF. Here, we describe cellular antibody present survivors (N = 370) their exposed contacts 170) LASV endemic region Nigeria. Interestingly, our data showed comparable T cell binding from both...
Abstract The majority of SARS-CoV-2 vaccines in use or advanced clinical development are based on the viral spike protein (S) as their immunogen. S is present virions pre-fusion trimers which receptor binding domain (RBD) stochastically open closed. Neutralizing antibodies have been described that act against both and closed conformations. long-term success vaccination strategies will depend upon inducing provide long-lasting broad immunity evolving, circulating strains, while avoiding risk...
Abstract Approximately 75% of the UK population has received only one dose a 2-dose COVID-19 vaccine regime in face circulating SARS-CoV-2 Variants Concern (VOCs). We aimed to determine levels vaccine-induced neutralising antibodies variants B.1.1.7, B.1.351 and P.1. To do so, we undertook single-centre cross-sectional study health care workers (HCWs) outpatients with immunodeficiencies (IDP) based at same critical tertiary NHS Trust, following single either BNT162b2 or AZD1222 vaccines....
ABSTRACT The increasing global spread of the highly pathogenic avian influenza (HPAI) A/H5 viruses poses a serious public health threat. Circulating clade 2.3.4.4b have demonstrated rapid transcontinental dissemination, extensive reassortment, epizootic and potential sustained mammal-to-mammal transmission, signifying heightened risk becoming human pathogen high consequence. A broadly protective, future-proof vaccine against multiple clades H5 is urgently needed for pandemic preparedness....